Ignace B. Vergote, MD, PhD, discusses the need to develop novel therapies in endometrial cancer.
Ignace B. Vergote, MD, PhD, head of the Department of Obstetrics and Gynecology and Gynecologic Oncology, Catholic University of Leuven, Belgium, discusses the need to develop novel therapies in endometrial cancer.
Endometrial cancer is the most frequent gynecologic malignancy among women in the United States, says Vergote. Additionally, endometrial cancer has a high mortality and morbidity rate.
The current standard of care for patients with endometrial cancer is platinum-based chemotherapy in combination with a taxane, explains Vergote.
However, there are no established treatment options for patients who recur after first-line therapy, Vergote adds.
As such, developing novel therapies to treat patients who recur, maintaining remissions after first-line therapy, and extending the time patients are not on chemotherapy remain unmet clinical needs in endometrial cancer, concludes Vergote.